Greg Weaver
About Greg Weaver
Greg Weaver is the Chief Financial Officer with over 30 years of experience in life sciences, financial, and operations roles, having served as CFO at Atossa Therapeutics, BioIntelliSense, atai Life Sciences, and Eloxx Pharmaceuticals.
Greg Weaver Chief Financial Officer
Greg Weaver currently holds the position of Chief Financial Officer. He brings more than 30 years of experience in life sciences, finance, and operations to his role. Weaver's extensive background includes serving as CFO for multiple companies in the biopharmaceutical and medical technology sectors, demonstrating his ability to manage complex financial and operational challenges.
Greg Weaver Atossa Therapeutics
Greg Weaver has served as the Chief Financial Officer of Atossa Therapeutics, Inc. Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics and delivery methods for breast cancer and other breast conditions. As CFO, Weaver oversees the company's financial operations, ensuring strategic financial planning and reporting.
Greg Weaver BioIntelliSense
Greg Weaver held the position of Chief Financial Officer at BioIntelliSense, a commercial stage medical technology company. BioIntelliSense specializes in remote patient monitoring solutions. During his tenure, he played a key role in financial planning and analysis, contributing to the company's mission of transforming healthcare through advanced technology solutions.
Greg Weaver atai Life Sciences
At atai Life Sciences, Greg Weaver served as CFO and was instrumental in completing over $282 million in late-stage private financings. He also led the company to a successful Initial Public Offering (IPO), raising $258 million. Atai Life Sciences focuses on developing innovative treatments for mental health conditions, and Weaver's financial leadership significantly contributed to the company's growth and public entry.
Greg Weaver Eloxx Pharmaceuticals
Greg Weaver previously served as the Chief Financial Officer of Eloxx Pharmaceuticals, Inc. Eloxx Pharmaceuticals is dedicated to developing novel therapeutics for rare and ultra-rare genetic diseases. In his role as CFO, Weaver managed the company's financial strategies, helping to drive its mission forward in addressing critical unmet medical needs.
Greg Weaver Mergers and Acquisitions
Greg Weaver has extensive experience managing mergers and acquisitions (M&A) in the life sciences sector. His expertise includes handling transactions involving oncology products, medical device technologies, and other biotech assets. Weaver's M&A experience has been critical in aligning financial strategies with business growth and development objectives.